Long-Term Efficacy and Safety of Add-On Therapy of Sitagliptin to a Very Small Dose of Glimepiride Versus a Small Dose of Glimepiride Over Eighteen Months

Background: In patients associated with type 2 diabetes mellitus, sulfonylureas (SUs) are being prescribed less frequently, and in smaller doses, to avoid hypoglycemia and body weight gain. On the other hand, since dipeptidyl peptidase-4 (DPP-4) inhibitors only infrequently induce hypoglycemia and weight gain, more than 60% or 70% of Japanese patients associated with type 2 diabetes mellitus are currently being treated with DPP-4 inhibitors. However, the long-term effects of DPP-4 inhibitors on glycemic control and ?-cell function have not been thoroughly elucidated. Methods: The present study was designed to compare the long-term efficacy and safety of a daily administration of 50 mg sitagliptin added to a very small dose of glimepiride, SUs, of 1.1 mg (SIT group), versus a small dose of glimepiride added by 1 mg to its basal dosage, i.e., 2.1 mg (SU group) up to 18 months in Japanese patients with type 2 diabetes mellitus. Sixty patients, aged 20 to 75 years with hemoglobin A1c (HbA1c) between 7.4% and 9.0% on glimepiride with or without metformin, were randomized into two groups. If the target (HbA1c ? 6.9% or fasting plasma glucose level ? 130 mg/dL) was not achieved, sitagliptin or glimepiride, respectively, was increased. Results: After 18 months, HbA1c had significantly decreased to 7.1-7.2% in both groups (P < 0.01). Plasma levels of insulin and proinsulin remained unchanged during the study. However, the proinsulin/insulin ratio was significantly lower after 6 months and thereafter only in the SU group. Homeostasis model assessment-? cell (HOMA-?) demonstrated a significant augmentation at some points during the study in both groups. No severe hypoglycemic episodes or body weight gain were seen in either group. Conclusions: Add-on therapy of 50 mg of sitagliptin to a very small dose of glimepiride at 1.1 to 1.2 mg/day, or a small dose of glimepiride at 2.1 mg/day, proved effective for improving or maintaining glycemic control without deterioration of ?-cell function over 18 months. J Endocrinol Metab. 2019;9(6):171-179 doi: https://doi.org/10.14740/jem621

[1]  L. Niskanen,et al.  Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION) , 2015, Diabetes, obesity & metabolism.

[2]  H. Vestergaard,et al.  Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. , 1999, Diabetes care.

[3]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[4]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[5]  R. Schwartz,et al.  Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1998, The Journal of clinical endocrinology and metabolism.

[6]  Y. Ohno,et al.  Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study , 2015, Diabetology International.

[7]  Yuichiro Yamada,et al.  Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial) , 2017, Diabetes, obesity & metabolism.

[8]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[9]  M. Marre,et al.  Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency , 2013, Diabetes Care.

[10]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  J. Holst,et al.  Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[13]  R. Holman,et al.  The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. , 1997, Metabolism: clinical and experimental.

[14]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[15]  R. Goldberg,et al.  A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. , 1996, Diabetes care.

[16]  C. Cobelli,et al.  Effect of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on beta‐cell function in patients with type 2 diabetes: a model‐based approach , 2008, Diabetes, obesity & metabolism.

[17]  H. Nawata,et al.  Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. , 2000, Endocrine journal.

[18]  R. Gallop,et al.  Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes , 2014, Diabetes Care.

[19]  R. DeFronzo,et al.  Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes , 2013, Diabetes Care.

[20]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  Y. Iwamoto,et al.  Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. , 2010, Endocrine journal.

[22]  Masahiko Kato,et al.  The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study , 2013, BMC Research Notes.

[23]  B. Zinman,et al.  Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy Short title: Glucagon after vildagliptin versus glimepiride , 2010 .

[24]  T. Forst,et al.  In Type 2 Diabetes Patients, Insulin Glargine is Associated with Lower Postprandial Release of Intact Proinsulin Compared with Sulfonylurea Treatment , 2012, Journal of diabetes science and technology.